Review ArticleReview Article
Open Access

BRCA2 gene mutation and prostate cancer risk

Comprehensive review and update

Noor N. Junejo and Sultan S. AlKhateeb
Saudi Medical Journal January 2020, 41 (1) 9-17; DOI: https://doi.org/10.15537/smj.2020.1.24759

References

  1. ↵
    1. Bray F,
    2. Ferlay J,
    3. Soerjomataram I,
    4. Siegel RL,
    5. Torre LA,
    6. Jemal A,
    7. et al.
    (2018) Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kvale R,
    2. Myklebust TA,
    3. Engholm G,
    4. Heinävaara S,
    5. Wist E,
    6. Moller B
    (2017) Prostate and breast cancer in four Nordic countries:a comparison of incidence and mortality trends across countries and age groups 1975-2013. Int J Cancer 141:2228–2242.
    OpenUrl
  3. ↵
    1. Saudi Cancer Registry
    (2010) Annual Report, Available from: https://shc.gov.sa/Arabic/Pages/default.aspx.
  4. ↵
    1. Mosli HA
    (2003) Prostate cancer in Saudi Arabia in 2002. Saudi Med J 24:573–581.
    OpenUrlPubMed
  5. ↵
    1. Kehinde EO
    (2005) Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men 2005. BJU Int 96:308–312.
    OpenUrlPubMed
  6. ↵
    1. Alyaiya AA
    (2011) Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma. Int J Oncol 38:1047–1057.
    OpenUrlPubMed
  7. ↵
    1. Hemminki K,
    2. Li X,
    3. Czene K
    (2002) Cancer risks in first-generation immigrants to Sweden. Int J Cancer 99:218–228.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Visser O,
    2. van Leeuwen FE
    (2007) Cancer risk in first generation migrants in North-Holland/Flevoland, The Netherlands 1995-2004. Eur J Cancer 43:901–908.
    OpenUrlPubMed
  9. ↵
    1. Nasseri K,
    2. Mills P,
    3. Allan A
    (2007) Cancer incidence in the Middle Eastern population of California 1988-2004. Asian Pac J Cancer Prev 8:405–411.
    OpenUrlPubMed
  10. ↵
    1. Hanash K,
    2. Al-Othaimeen A,
    3. Kattan S,
    4. Lindstedt E,
    5. Al-Zahrani H
    (2000) Prostatic carcinoma:a nutritional disease?Conflicting data from the Kingdom of Saudi Arabia. J Urol 164:1570–1572.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. American Cancer Society
    (2019) Cancer Facts and Figures 2019 (American Cancer Society, Atlanta (GA)).
  12. ↵
    1. Salinas CA,
    2. Tsodikov A,
    3. Ishak-Howard M,
    4. Cooney KA
    (2014) Prostate cancer in young men:an important clinical entity. Nat Rev Urol 11:317–323.
    OpenUrlPubMed
  13. ↵
    1. Hjelmborg JB,
    2. Scheike T,
    3. Holst K,
    4. Skytthe A,
    5. Penney KL,
    6. Graff RE,
    7. et al.
    (2014) The heritability of prostate cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomarkers Prev 23:2303–2310.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Steinberg GD,
    2. Carter BS,
    3. Beaty TH,
    4. Childs B,
    5. Walsh PC
    (1990) Family history and the risk of prostate cancer. Prostate 17:337–347.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Stanford JL,
    2. Ostrander EA
    (2001) Familial prostate cancer. Epidemiol Rev 23:19–23.
    OpenUrlPubMedWeb of Science
  16. ↵
    1. Matikaine MP,
    2. Pukkala E,
    3. Schleutker J,
    4. Tammela TL,
    5. Koivisto P,
    6. Sankila R,
    7. et al.
    (2000) Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers:a population-based, cancer registry study in Finland. Cancer Causes Control 12:223–230.
    OpenUrl
  17. ↵
    1. Bratt O,
    2. Garmo H,
    3. Adolfsson J,
    4. Bill-Axelson A,
    5. Holmberg L,
    6. Lambe M,
    7. et al.
    (2010) Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 102:1336–1343.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Jacqueline Mersch,
    2. Michelle A,
    3. Jackson,
    4. Minjeong Park,
    5. Denise Nebgen,
    6. Susan K
    (2015) Peterson, Claire Singletary, et al. Cancer. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121:269–275.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Giri VN,
    2. Beebe-Dimmer JL
    (2016) Familial prostate cancer. Seminoncol 43:560–565.
    OpenUrlCrossRef
  20. ↵
    1. Pritchard CC,
    2. Mateo J,
    3. Walsh MF,
    4. De Sarkar N,
    5. Abida W,
    6. Beltran H,
    7. et al.
    (2016) Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 375:443–453.
    OpenUrlCrossRefPubMed
    1. Castro E,
    2. Romero-Laorden N,
    3. Del Pozo A,
    4. Lozano R,
    5. Medina A,
    6. Puente J,
    7. et al.
    (2019) PROREPAIR-B:A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 37:490–503.
    OpenUrl
  22. ↵
    1. Castro E,
    2. Goh C,
    3. Leongamornlert D,
    4. Saunders E,
    5. Tymrakiewicz M,
    6. Dadaev T,
    7. et al.
    (2015) Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localized prostate cancer. Eur Urol 68:186–193.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Robinson D,
    2. Eliezer M,
    3. van Allen,
    4. Schultz N,
    5. Lonigro RJ,
    6. Mosquera JM,
    7. et al.
    (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161:1215–1228.
    OpenUrlCrossRefPubMed
    1. Joaquin Mateo,
    2. Suzanne Carreira,
    3. Shahneen Sandhu,
    4. Susana Miranda,
    5. Helen Mossop,
    6. Raquel Perez-Lopez,
    7. et al.
    (2015) DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 373:1697–1708.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Kasmintan A,
    2. Schrader Donavan T
    (2016) Cheng, Vijai Joseph, Meera Prasad, Michael Walsh, Ahmet Zehir, et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncol 2:104–111.
    OpenUrl
  26. ↵
    1. King M-C,
    2. Marks JH,
    3. Mandell JB,
    4. New York Breast Cancer Study Group
    (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Schoenborn JR,
    2. Nelson P,
    3. Fang M
    (2013) Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res 19:4058–4066.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Zack TI,
    2. Schumacher SE,
    3. Carter SL,
    4. Cherniack AD,
    5. Saksena G,
    6. Tabak B,
    7. et al.
    (2013) Pan-cancer patterns of somatic copy number alteration. Nat Gen 45:1134–1139.
    OpenUrlCrossRefPubMed
    1. Grasso CS,
    2. Wu YM,
    3. Robinson DR,
    4. Dhanasekaran SM,
    5. Khan AP,
    6. Quist MJ,
    7. et al.
    (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239–243.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Kumar A,
    2. White TA,
    3. MacKenzie AP,
    4. Clegg N,
    5. Lee C,
    6. Dumpit RF,
    7. et al.
    (2011) Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci USA 108:17087–17092.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Bisbal C,
    2. Silverman RH
    (2007) Diverse functions of RNase L and implications in pathology. Biochimie 89:789–798.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Takaku H,
    2. Minagawa A,
    3. Takagi M,
    4. Nashimotoet M
    (2003) A candidate prostate cancer susceptibility gene encodes tRNA 3 processing endoribonuclease. Nucleic Acids Res 31:2272–2278.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Beuten J,
    2. Gelfond JAL,
    3. Franke JL,
    4. Shook S,
    5. Teresa L,
    6. Johnson-Pais,
    7. Thompson Ian M,
    8. et al.
    (2010) Single and multivariate associations of MSR1, ELAC2, and RNase L with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev 19:588–599.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Ewing CM,
    2. Ray AM,
    3. Lange EM,
    4. Zuhlke KA,
    5. Robbins CM,
    6. Tembe WD,
    7. et al.
    (2012) Germ line mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366:141–149.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. Risbridger G. P,
    2. Taylor RA,
    3. Clouston D,
    4. Sliwinski A,
    5. Thorne H,
    6. Hunter S,
    7. et al.
    (2015) Patient- derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur Urol 67:496–503.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Porter LH,
    2. Lawrence MG,
    3. Ilic D,
    4. Clouston D,
    5. Bolton DM,
    6. Frydenberg M,
    7. et al.
    (2017) Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories. Eur Urol 72:492–495.
    OpenUrl
  37. ↵
    1. Taylor RA,
    2. Fraser M,
    3. Rebello RJ,
    4. Boutros PC,
    5. Murphy DG,
    6. Bristow RG,
    7. et al.
    (2019) The influence of BRCA2 mutation on localized prostate cancer. Nat Rev Urol 16:281–229.
    OpenUrlCrossRef
  38. ↵
    1. Castro E,
    2. Mateo J,
    3. Olmos D,
    4. de Bono JS
    (2016) Targeting DNA repair:The role of PARP inhibition in the treatment of castration resistant prostate cancer. Cancer J 22:353–356.
    OpenUrlCrossRef
  39. ↵
    1. Armenia J,
    2. Wankowicz S.A.M,
    3. Liu D,
    4. Gao J,
    5. Kundra R,
    6. Reznik E,
    7. et al.
    (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645–651.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Narod SA,
    2. Neuhausen S,
    3. Vichodez G,
    4. Armel S,
    5. Lynch HT,
    6. Ghadirian P,
    7. et al.
    (2008) Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99:371–374.
    OpenUrlCrossRefPubMedWeb of Science
    1. Gallagher DJ,
    2. Gaudet MM,
    3. Pal P,
    4. Kirchhoff T,
    5. Balistreri L,
    6. Vora K,
    7. et al.
    (2010) Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 16:2115–2121.
    OpenUrlAbstract/FREE Full Text
    1. Thorne H,
    2. Willems A.J,
    3. Niedermayr E,
    4. Hoh I.M,
    5. Li J,
    6. Clouston D,
    7. et al.
    (2011) Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res 4:1002–1010.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Castro E,
    2. Goh C,
    3. Olmos D,
    4. Saunders E,
    5. Leongamornlert D,
    6. Tymrakiewicz M,
    7. et al.
    (2013) Germline BRCA mutations are associated with a higher risk of nodal involvement, distant metastasis and poor survival outcomes in prostate cancer. J Clin Oncol 31:1748–1757.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Cheng H.H,
    2. Pritchard C.C,
    3. Boyd T,
    4. Nelson P.S,
    5. Montgomery B
    (2016) Biallelic Inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol 69:992–995.
    OpenUrl
  45. ↵
    1. Zafeiriou Z,
    2. Bianchini D,
    3. Chandler R,
    4. Rescigno P,
    5. Yuan W,
    6. Carreira S,
    7. et al.
    (2019) Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. Eur Urol 75:184–192.
    OpenUrl
    1. Pomerantz MM,
    2. Spisak S,
    3. Jia L,
    4. Cronin AM,
    5. Csabai I,
    6. Ledet E,
    7. et al.
    (2017) The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 123:3532–3539.
    OpenUrlCrossRef
  47. ↵
    1. Mateo J,
    2. Carreira S,
    3. Sandhu S,
    4. Miranda S,
    5. Mossop H,
    6. Perez-Lopez R,
    7. et al.
    (2015) DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 373:1697–1708.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Nombela P,
    2. Lozano R,
    3. Aytes A,
    4. Mateo J,
    5. Olmos D,
    6. Castro E
    (2019) BRCA2 and Other DDR Genes in Prostate Cancer. Cancers 11:352.
    OpenUrl
  49. ↵
    1. Bancroft E.K,
    2. Page E.C,
    3. Castro E,
    4. Lilja H,
    5. Vickers A,
    6. Sjoberg D,
    7. et al.
    (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers:Results from the initial screening round of the IMPACT study. Eur Urol 66:489–499.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Kasivisvanathan V,
    2. Rannikko A.S,
    3. Borghi M,
    4. Panebianco V,
    5. Mynderse L.A,
    6. Vaarala M.H,
    7. et al.
    (2018) MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 378:1767–1777.
    OpenUrlPubMed
  51. ↵
    1. Nielsen F.C,
    2. van Overeem Hansen T,
    3. Sorensen C.S
    (2016) Hereditary breast and ovarian cancer:New genes in confined pathways. Nat Rev Cancer 16:599–612.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Zhen JT,
    2. Syed J,
    3. Nguyen KA,
    4. Leapman MS,
    5. Agarwal N,
    6. Brierley K,
    7. et al.
    (2018) Genetic testing for hereditary prostate cancer:Current status and limitations. Cancer 124:3105–3117.
    OpenUrl
  53. ↵
    1. Hart SN,
    2. Ellingson MS,
    3. Schaal K,
    4. Vedell PT,
    5. Carlson RE,
    6. Sinnwell JP,
    7. et al.
    (2016) Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open 6:e010332.
    OpenUrlAbstract/FREE Full Text
    1. Na R,
    2. Zheng SL,
    3. Han M,
    4. Yu H,
    5. Jiang D,
    6. Shah S,
    7. et al.
    (2017) Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol 71:740–747.
    OpenUrl
  55. ↵
    1. Beltran H,
    2. Eng K,
    3. Mosquera JM,
    4. Sigaras A,
    5. Romanel A,
    6. Rennert H,
    7. et al.
    (2015) Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol 1:466–474.
    OpenUrl
  56. ↵
    1. Cheng HH,
    2. Pritchard CC,
    3. Boyd T,
    4. Nelson PS
    (2016) Montgomery Bet al:Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol 69:992–995.
    OpenUrl
  57. ↵
    1. Giri VN,
    2. Obeid E,
    3. Gross L,
    4. Bealin L,
    5. Hyatt C,
    6. Hegarty SE,
    7. et al.
    (2017) Inherited mutations in men undergoing multigene panel testing for prostate cancer:emerging implications for personalized prostate cancer genetic evaluation. J Precis Oncol JCO Precision Oncology 1:1–17.
    OpenUrl
  58. ↵
    1. Kote-Jarai Z,
    2. Leongamornlert D,
    3. Saunders E,
    4. Tymrakiewicz M,
    5. Castro E,
    6. Mahmud N,
    7. et al.
    (2011) BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer:implications for genetic testing in prostate cancer patients. Br J Cancer 105:1230–1234.
    OpenUrlCrossRefPubMedWeb of Science
  59. ↵
    1. Robson ME,
    2. Bradbury AR,
    3. Arun B,
    4. Domchek SM,
    5. Ford JM,
    6. Hampel HL,
    7. et al.
    (2015) American Society of Clinical Oncology policy statement update:genetic and genomic testing for cancer susceptibility. J Clin Oncol 33:3660–3667.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Bancroft EK,
    2. Saya S,
    3. Page EC,
    4. Myhill K,
    5. Thomas S,
    6. Pope J,
    7. et al.
    (2019) Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. BJU Int 123:284–292.
    OpenUrl
  61. ↵
    1. Byrski T,
    2. Gronwald J,
    3. Huzarski T,
    4. Grzybowska E,
    5. Budryk M,
    6. Stawicka M,
    7. et al.
    (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375–379.
    OpenUrlAbstract/FREE Full Text
    1. Von Minckwitz G,
    2. Schneeweiss A,
    3. Loibl S,
    4. Salat C,
    5. Denkert C,
    6. Rezai M,
    7. et al.
    (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto;GBG 66):A randomized phase 2 trial. Lancet Oncol 15:747–756.
    OpenUrlCrossRefPubMedWeb of Science
  63. ↵
    1. Yang D,
    2. Khan S,
    3. Sun Y,
    4. Hess K,
    5. Shmulevich I,
    6. Sood A.K,
    7. et al.
    (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306:1557–1565.
    OpenUrlCrossRefPubMedWeb of Science
  64. ↵
    1. Hager S,
    2. Ackermann C.J,
    3. Joerger M,
    4. Gillessen S,
    5. Omlin A
    (2016) Anti-tumor activity of platinum compounds in advanced prostate cancer-a systematic literature review. Ann Oncol 27:975–984.
    OpenUrlCrossRefPubMed
  65. ↵
    1. Pomerantz MM,
    2. Spisak S,
    3. Jia L,
    4. Cronin AM,
    5. Csabai I,
    6. Ledet E,
    7. et al.
    (2017) The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 123:3532–3539.
    OpenUrlCrossRef
  66. ↵
    1. Morales J,
    2. Li L,
    3. Fattah FJ,
    4. Dong Y,
    5. Bey EA,
    6. Patel M,
    7. et al.
    (2014) Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr 24:15–28.
    OpenUrlCrossRefPubMed
  67. ↵
    1. Lord CJ,
    2. Tutt AN,
    3. Ashworth A
    (2015) Synthetic lethality and cancer therapy:Lessons learned from the development of PARP inhibitors. Annu Rev Med 66:455–470.
    OpenUrlCrossRefPubMed
  68. ↵
    1. Sonpavde G,
    2. Di Lorenzo G,
    3. Higano CS,
    4. Kantoff PW,
    5. Madan R,
    6. Shore ND
    (2012) The role of sipuleucel-T in therapy for castration-resistant prostate cancer:a critical analysis of the literature. Eur Urol 61:639–634.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Kantoff PW,
    2. Schuetz TJ,
    3. Blumenstein BA,
    4. Glode LM,
    5. Bilhartz DL,
    6. Wyand M,
    7. et al.
    (2010) Overall survival analysis of phase II randomized controlled trial of Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099–1105.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Thorne H,
    2. Willems AJ,
    3. Niedermayr E,
    4. Hoh IM,
    5. Li J,
    6. Clouston D,
    7. et al.
    (2011) Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res 4:1002–1010.
    OpenUrlAbstract/FREE Full Text
  71. ↵
    1. Caffo O,
    2. Veccia A,
    3. Kinspergher S,
    4. Rizzo M,
    5. Maines F
    (2018) Aberrations of DNA Repair Pathways in Prostate Cancer:Future Implications for Clinical Practice? Front Cell Dev Biol 5:61.
    OpenUrl
    1. Akbari MR,
    2. Wallis CJ,
    3. Toi A,
    4. Trachtenberg J,
    5. Sun P,
    6. Narod SA,
    7. et al.
    (2014) The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. Br J Cancer 111:1238–1240.
    OpenUrl
    1. Edwards SM,
    2. Kote-Jarai Z,
    3. Meitz J,
    4. Hamoudi R,
    5. Hope Q,
    6. Osin P,
    7. et al.
    (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72:1–12.
    OpenUrlCrossRefPubMedWeb of Science
    1. Kirchhoff T,
    2. Kauff ND,
    3. Mitra N,
    4. Nafa K,
    5. Huang H,
    6. Palmer C,
    7. et al.
    (2004) BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10:2918–2921.
    OpenUrlAbstract/FREE Full Text
    1. Sinclair CS,
    2. Berry R,
    3. Schaid D,
    4. Thibodeau SN,
    5. Couch FJ
    (2000) BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 60:1371–1375.
    OpenUrlAbstract/FREE Full Text
    1. Maier C,
    2. Herkommer K,
    3. Luedeke M,
    4. Rinckleb A,
    5. Schrader M,
    6. Vogel W
    (2014) Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations. Prostate 74:1444–1451.
    OpenUrl
    1. Ikonen T,
    2. Matikainen MP,
    3. Syrjäkoski K,
    4. Mononen N,
    5. Koivisto PA,
    6. Rökman A,
    7. et al.
    (2003) BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. J Med Genet 40:e98.
    OpenUrlFREE Full Text
    1. Manguoğlu E,
    2. Güran S,
    3. Yamaç D,
    4. Colak T,
    5. Simşek M,
    6. Baykara M,
    7. et al.
    (2010) Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients. Cancer Genet Cytogenet 203:230–237.
    OpenUrlPubMed
    1. Tryggvadóttir L,
    2. Vidarsdóttir L,
    3. Thorgeirsson T,
    4. Jonasson JG,
    5. Olafsdóttir EJ,
    6. Olafsdóttir GH
    (2007) Prostate cancer progression, and survival in BRCA2 mutation carriers. J Natl Cancer Inst 99:929–935.
    OpenUrlCrossRefPubMed
    1. Agalliu I,
    2. Gern R,
    3. Leanza S,
    4. Burk RD
    (2009) Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 15:1112–1120.
    OpenUrlAbstract/FREE Full Text
    1. Attard G,
    2. Parker C,
    3. Eeles RA,
    4. Schröder F,
    5. Tomlins SA,
    6. Tannock I,
    7. et al.
    (2016) Prostate cancer. Lancet 387:70–82.
    OpenUrlCrossRefPubMed
    1. Artibani W,
    2. Porcaro AB,
    3. De Marco V,
    4. Cerruto MA,
    5. Siracusano S
    (2018) Management of biochemical recurrence after primary curative treatment for prostate cancer:a review. Urol Int 100:251–262.
    OpenUrl
    1. Castro E,
    2. Jugurnauth-Little S,
    3. Karlsson Q,
    4. Al-Shahrour F,
    5. Piñeiro-Yañez E,
    6. Van de Poll SF,
    7. et al.
    (2015) High burden of copy number alterations and c- MYC amplification in prostate cancer from BRCA2 germline mutation carriers. Ann Oncol 26:2293–2300.
    OpenUrlCrossRefPubMed
    1. Fraser M,
    2. Sabelnykova VY,
    3. Yamaguchi TN,
    4. Heisler LE,
    5. Livingstone J,
    6. Huang V,
    7. et al.
    (2017) Genomic hallmarks of localized, non- indolent prostate cancer. Nature 541:359–364.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords